This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of Patient Reported Outcome Instruments in Celiac Disease Patients

This study has been completed.
Information provided by (Responsible Party):
Alvine Pharmaceuticals Inc. Identifier:
First received: March 20, 2012
Last updated: October 9, 2013
Last verified: October 2013
This is an evaluation of celiac-specific patient reported outcome instruments in celiac disease patients.

Celiac Disease

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Clinical Evaluation of Three Celiac Disease-Specific Patient Reported Outcome Instruments in Established and Newly Diagnosed Celiac Disease Patients

Resource links provided by NLM:

Further study details as provided by Alvine Pharmaceuticals Inc.:

Primary Outcome Measures:
  • Change in symptoms using patient reported outcome instruments [ Time Frame: 8 and 12 weeks ]
    Sensitivity of the patient reported outcome instruments to detect change over time in celiac disease symptoms with and without a gluten challenge

Secondary Outcome Measures:
  • Safety - incidence of adverse events [ Time Frame: 8 and 12 weeks ]
    Safety will be evaluated by incidents of adverse events including clinical significant laboratory evaluations and serious adverse events

Enrollment: 110
Study Start Date: March 2012
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Gluten challenge
Gluten containing or gluten-free study food in established celiac disease patients
Observation in newly diagnosed celiac disease patients


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Biopsy proven celiac disease patients

Inclusion Criteria:

  • History of biopsy proven celiac disease
  • Adherence to a gluten-free diet (established patients only)
  • TG2 negative (established patients only)
  • TG2 positive (newly diagnosed patients only)
  • Signed informed consent

Exclusion Criteria:

  • History of IgE-mediated reactions to gluten
  • Significant laboratory abnormalities
  • History of untreated or GI disease
  • Positive pregnancy test
  • Any medical condition which could adversely affect study participation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01560169

United States, California
University of California, San Diego
La Jolla, California, United States, 92037
Kaiser Permanente Southern California, Allergy Department
San Diego, California, United States, 92111
United States, Colorado
University of Colorado, Denver
Aurora, Colorado, United States, 80045
United States, Illinois
University of Chicago Celiac Disease Center
Chicago, Illinois, United States, 60637
United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, New York
Columbia University
New York City, New York, United States, 10032
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Canada, Alberta
University of Alberta
Edmonton, Alberta, Canada, T6G 2X8
Sponsors and Collaborators
Alvine Pharmaceuticals Inc.
Study Chair: Daniel Adelman, MD Alvine Pharmaceuticals Inc.
  More Information

Responsible Party: Alvine Pharmaceuticals Inc. Identifier: NCT01560169     History of Changes
Other Study ID Numbers: ALV003-1121
Study First Received: March 20, 2012
Last Updated: October 9, 2013

Keywords provided by Alvine Pharmaceuticals Inc.:
Celiac Disease
Coeliac Disease
Celiac Sprue
Keilakia Disease

Additional relevant MeSH terms:
Celiac Disease
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Metabolic Diseases processed this record on September 19, 2017